Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis

We assessed vaccination-induced antibody and cellular response against spike from the ancestral strain and from the Delta Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) variant in patients with Multiple Sclerosis (MS) treated with disease modifying treatments. We enrolled 47 patients w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in neurology Jg. 13; S. 881988
Hauptverfasser: Petrone, Linda, Tortorella, Carla, Aiello, Alessandra, Farroni, Chiara, Ruggieri, Serena, Castilletti, Concetta, Meschi, Silvia, Cuzzi, Gilda, Vanini, Valentina, Palmieri, Fabrizio, Prosperini, Luca, Haggiag, Shalom, Galgani, Simona, Grifoni, Alba, Sette, Alessandro, Gasperini, Claudio, Nicastri, Emanuele, Goletti, Delia
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 31.05.2022
Schlagworte:
COVID-19
DMTs
immune response
multiple sclerosis
Neurology
T-response
vaccine
COVID-19
DMTs
vaccine
immune response
T-response
multiple sclerosis
ISSN:1664-2295, 1664-2295
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We assessed vaccination-induced antibody and cellular response against spike from the ancestral strain and from the Delta Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) variant in patients with Multiple Sclerosis (MS) treated with disease modifying treatments. We enrolled 47 patients with MS and nine controls ("no MS") having completed the vaccination schedule within 4-6 months from the first dose. The Interferon (IFN)-γ-response to spike peptides derived from the ancestral and the Delta SARS-CoV-2 was measured by enzyme-linked immunoassay (ELISA). Anti-Receptor Binding Domain (RBD) IgG were also evaluated. No significant differences were found comparing the IFN-γ-specific immune response between MS and "no MS" subjects to the ancestral ( = 0.62) or Delta peptide pools ( = 0.68). Nevertheless, a reduced IFN-γ-specific response to the ancestral or to the Delta pools was observed in subjects taking fingolimod or cladribine compared to subjects treated with ocrelizumab or IFN-β. The antibody response was significantly reduced in patients with MS compared to "no MS" subjects ( = 0.0452) mainly in patients taking ocrelizumab or fingolimod. Cellular responses to Delta SARS-CoV-2 variant remain largely intact in patients with MS. However, the magnitude of these responses depends on the specific therapy.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
These authors have contributed equally to this work
Reported in the Acknoweldgments section
Present address: Concetta Castilletti, Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy
Edited by: Marat Fudim, Duke University, United States
Reviewed by: Pavan Bhargava, Johns Hopkins Medicine, United States; Ricardo Alonso, Hospital Ramos Mejía, Argentina
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2022.881988